Rimegepant - Migraine (acute)
You are here : Home > Formulary Search > Rimegepant - Migraine (acute)
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Status 1
Green
Formulations :
- Oral lyophilisates
Formulary Status :
Restrictions / Comments :
Documents :
NICE Technology Appraisal
Documentation
- No records returned.
PAD Profile
ChemicalSubstance :
Rimegepant
Indication :
Migraine (acute)
Group Name :
Keywords :
Acute migraine, migraine treatment, calcitonin gene-related peptide inhibitors, CGRP antagonists
Brand Names Include :
Vydura
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
2
Other Indications
Below are listed other indications that Rimegepant is used to treat.
Other Drugs
Below are listed other drugs that are used to treat Migraine (acute).
Committee Recommendations (1)
The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approves rimegepant for the acute treatment of Migraine with or without aura in adults in line with NICE TA919.
A GREEN traffic light status has been agreed.
Treatment with rimegepant for acute migraine is recommended by NICE, only if for previous migraines:
- at least 2 triptans were tried and these did not work well enough or
- triptans were contraindicated or not tolerated, and nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol were tried but did not work well enough.
Patients receiving 8 or more tablets per month should be considered for preventative treatment.